Gracell Biotechnologies Inc - ADR

NASDAQ:GRCL   2:22:08 PM EDT
3.25
+0.07 (+2.20%)
Earnings Announcements

Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results And Provides Corporate Update

Published: 11/14/2022 13:41 GMT
Gracell Biotechnologies Inc - ADR (GRCL) - Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update.
Well-funded With Cash Runway for Next 24 Months.
Qtrly Net Loss per Share Attributable to Gracell Biotechnologies Inc's Ordinary Shareholders Rmb 0.51.
Q3 Earnings per Share View $-0.13 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.08

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.08

More details on our Analysts Page.